IL1B and breast carcinoma: Furthermore, pharmacological inhibition of IL-1 signalling (via 12 ng/mL MLX01: Py8119, p = 0.0003; 25 ng/mL VRT043198: p = 0.0283; and 0.1 mg/mL Anakinra) increased invasion of breast cancer cells to HUVEC cells (Figure S4C).